Prestigious accolade for immunotherapy in Type 1 Diabetes research
Dr Mohammad Alhadj Ali picked up the 2018 training award from his work on immunotherapy for Type 1 diabetes.
Dr Alhadj Ali presented at the annual ABCD trainees meeting in London and was the co-winner out of four presentations that were shortlisted for the award.
Dr Alhadj Ali said “I am thrilled and honoured to have received the Training Award 2018 from Association of British Clinical Diabetologists in London.
“To be recognized by the senior faculty for my work in a research area as important as immunotherapy for Type 1 Diabetes, and to receive this prestigious award, is very special.”
Dr Graham Shortland, Executive Medical Director at Cardiff and Vale UHB said:
“Clinical Research is so important in developing treatment for patients. It enables healthcare staff to ensure patients receive the best care available and that medicine is effective in the treatment of conditions. It is fantastic that Dr Ali has been recognised for his research into Type 1 Diabetes which is a common illness that through his work could be better managed and treated, giving patients a better quality of life.”
Dr Alhadj Ali had been instrumental in Type 1 Diabetes clinical research and is part of the Diabetes Research Group at Cardiff University. He has also been the lead clinician in dosing the first two patients in a world first clinical trial which aims to regenerate cells in the pancreas so that people with Type 1 Diabetes become less reliant on insulin.
Cardiff’s Clinical Research Facility was the first centre to take part in this innovative clinical trial which if it works could be groundbreaking in the treatment of Type 1 Diabetes. There are still opportunities for people to take part in the trial. You can find out more at https://www.type1diabetesresearch.org.uk/